Uric Acid as a Risk Factor for Cardiovascular Disease and Mortality in Overweight/Obese Individuals

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Skak Nielsen, Helle ^a   Torp Pedersen, Christian ^a   Finer, Nick ^b   Caterson, Ian D ^c   van Gaal, Luc ^d   James, W Philip T ^e   Maggioni, Aldo Pietro ^f   Sharma, Arya M ^g   Coutinho, Walmir ^h   Andersson, Charlotte ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f ANMCO RESEARCH CENTER   (Italy)

^g UNIVERSITY OF ALBERTA   (Canada)

^h PONTIFICAL CATHOLIC UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SIBUTRAMINE; URIC ACID;

ADULT; ADVERSE OUTCOME; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART ARREST; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; URIC ACID BLOOD LEVEL;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; RISK FACTORS; TRIGLYCERIDES; URIC ACID;

EID: 84875336108     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059121     Document Type: Article

References (23)

1. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM, (2006) Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 37: 1503-1507.
2. Fang J, Alderman MH, (2000) Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 283: 2404-2410.
3. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G, (2009) Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 266: 558-570.
4. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, et al. (2004) Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 164: 1546-1551.
5. Freedman DS, Williamson DF, Gunter EW, Byers T, (1995) Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 141: 637-644.
6. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J, (1989) Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol 42: 257-267.
7. Culleton BF, Larson MG, Kannel WB, Levy D, (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 131: 7-13.
8. Ong G, Davis WA, Davis TM, (2010) Serum uric acid does not predict cardiovascular or all-cause mortality in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 53: 1288-1294.
9. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH, (2005) Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 45: 18-20.
10. Numata T, Miyatake N, Wada J, Makino H, (2008) Comparison of serum uric acid levels between Japanese with and without metabolic syndrome. Diabetes Res Clin Pract 80: e1-5.
11. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, et al. (2002) Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 87: 229-234.
12. Wei L, Mackenzie IS, Chen Y, Struthers AD, MacDonald TM, (2011) Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol 71: 600-607.
13. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486-2497.
14. Alberti KG, Zimmet PZ, (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553.
15. Alberti KG, Zimmet P, Shaw J, (2005) The metabolic syndrome-a new worldwide definition. Lancet 366: 1059-1062.
16. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, et al. (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363: 905-917.
17. Andersson C, Weeke P, Brendorp B, Kober L, Fosbol EL, et al. (2009) Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial. Nutr Metab (Lond) 6: 42.
18. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS, (2005) A review of the metabolic effects of sibutramine. Curr Med Res Opin 21: 457-468.
19. Reyes AJ, (2005) The increase in serum uric acid concentration caused by diuretics might be beneficial in heart failure. Eur J Heart Fail 7: 461-467.
20. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD, (2010) Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 375: 2161-2167.
21. Rajendra NS, Ireland S, George J, Belch JJ, Lang CC, et al. (2011) Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol 58: 820-828.
22. Feig DI, Kang DH, Johnson RJ, (2008) Uric acid and cardiovascular risk. N Engl J Med 359: 1811-1821.
23. Choi HK, Willett W, Curhan G, (2010) Fructose-rich beverages and risk of gout in women. JAMA 304: 2270-2278.